Modipafant

• UNSPSC Description:

  Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505[1][2].

• Target Antigen:

  Platelet-activating Factor Receptor (PAFR)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/modipafant.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C(C2=CC=C(N3C(C)=NC4=C3C=CN=C4)C=C2)NC(C)=C(C(NC5=NC=CC=C5)=O)[C@H]1C6=CC=CC=C6Cl)OCC

• Molecular Weight:

  605.09

• References & Citations:

  [1]Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995;151(5):1331-1335.|[2]Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996;26(9):963-975.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  122957-06-6